Kahl, K.G. Herrmann, J. Stubbs, B. Krüger, T.H.C. Cordes, J. Deuschle, M. Schweiger, U. Hüper, K. Helm, S. Birkenstock, A. and Hartung, D. 2017. Pericardial adipose tissue and the metabolic syndrome is increased in patients with chronic major depressive disorder compared to acute depression and controls. Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 72, p. 30.
Messamore, Erik Almeida, Daniel M. Jandacek, Ronald J. and McNamara, Robert K. 2017. Polyunsaturated fatty acids and recurrent mood disorders: Phenomenology, mechanisms, and clinical application. Progress in Lipid Research, Vol. 66, p. 1.
Zheng, Hong Zheng, Peng Zhao, Liangcai Jia, Jianmin Tang, Shengli Xu, Pengtao Xie, Peng and Gao, Hongchang 2017. Predictive diagnosis of major depression using NMR-based metabolomics and least-squares support vector machine. Clinica Chimica Acta, Vol. 464, p. 223.
Alosaimi, Fahad D. Abalhassan, Mohammed Alhaddad, Bandar Alzain, Nasser Fallata, Ebtihaj Alhabbad, Abdulhadi and Alassiry, Mohammed Z. 2016. Prevalence of metabolic syndrome and its components among patients with various psychiatric diagnoses and treatments: A cross-sectional study. General Hospital Psychiatry,
Fjukstad, Katrine Kveli Engum, Anne Lydersen, Stian Dieset, Ingrid Steen, Nils Eiel Andreassen, Ole A. and Spigset, Olav 2016. Metabolic Abnormalities Related to Treatment With Selective Serotonin Reuptake Inhibitors in Patients With Schizophrenia or Bipolar Disorder. Journal of Clinical Psychopharmacology, Vol. 36, Issue. 6, p. 615.
Hiles, Sarah A. Révész, Dóra Lamers, Femke Giltay, Erik and Penninx, Brenda W. J. H. 2016. BIDIRECTIONAL PROSPECTIVE ASSOCIATIONS OF METABOLIC SYNDROME COMPONENTS WITH DEPRESSION, ANXIETY, AND ANTIDEPRESSANT USE. Depression and Anxiety, Vol. 33, Issue. 8, p. 754.
Kahl, K.G. Kerling, A. Tegtbur, U. Gützlaff, E. Herrmann, J. Borchert, L. Ates, Zeynep Westhoff-Bleck, M. Hueper, K. and Hartung, D. 2016. Effects of additional exercise training on epicardial, intra-abdominal and subcutaneous adipose tissue in major depressive disorder: A randomized pilot study. Journal of Affective Disorders, Vol. 192, p. 91.
Kerling, Arno von Bohlen, Anne Kück, Momme Tegtbur, Uwe Grams, Lena Haufe, Sven Gützlaff, Elke and Kahl, Kai G. 2016. Exercise therapy improves aerobic capacity of inpatients with major depressive disorder. Brain and Behavior, Vol. 6, Issue. 6, p. e00469.
Lee, S H Paz-Filho, G Mastronardi, C Licinio, J and Wong, M-L 2016. Is increased antidepressant exposure a contributory factor to the obesity pandemic?. Translational Psychiatry, Vol. 6, Issue. 3, p. e759.
Liu, Xinyu Li, Jia Zheng, Peng Zhao, Xinjie Zhou, Chanjuan Hu, Chunxiu Hou, Xiaoli Wang, Haiyang Xie, Peng and Xu, Guowang 2016. Plasma lipidomics reveals potential lipid markers of major depressive disorder. Analytical and Bioanalytical Chemistry, Vol. 408, Issue. 23, p. 6497.
Moreira, Fernanda Pedrotti Jansen, Karen Mondin, Thaíse Campos Cardoso, Taiane de Azevedo Magalhães, Pedro Vieira da Silva Kapczinski, Flavio Frey, Benicio N. Oses, Jean Pierre Souza, Luciano Dias de Mattos da Silva, Ricardo Azevedo and Wiener, Carolina David 2016. Biological rhythms, metabolic syndrome and current depressive episode in a community sample. Psychoneuroendocrinology, Vol. 72, p. 34.
Nyboe, L. Vestergaard, C. H. Lund, H. Møller, M. K. and Videbech, P. 2016. Metabolic syndrome in first-time hospitalized patients with depression: a 1-year follow-up study. Acta Psychiatrica Scandinavica, Vol. 133, Issue. 3, p. 241.
Pietrzak, Max 2016. Adhesive capsulitis: An age related symptom of metabolic syndrome and chronic low-grade inflammation?. Medical Hypotheses, Vol. 88, p. 12.
Rosenblat, Joshua D. Kakar, Ron and McIntyre, Roger S. 2016. Cardiovascular Diseases and Depression.
Schmitz, N Deschênes, S S Burns, R J Smith, K J Lesage, A Strychar, I Rabasa-Lhoret, R Freitas, C Graham, E Awadalla, P and Wang, J L 2016. Depression and risk of type 2 diabetes: the potential role of metabolic factors. Molecular Psychiatry, Vol. 21, Issue. 12, p. 1726.
Stanton, Robert Reaburn, Peter and Happell, Brenda 2016. The Effect of Acute Exercise on Affect and Arousal in Inpatient Mental Health Consumers. The Journal of Nervous and Mental Disease, Vol. 204, Issue. 9, p. 658.
Vancampfort, Davy Hallgren, Mats Mugisha, James De Hert, Marc Probst, Michel Monsieur, Dirk and Stubbs, Brendon 2016. The Prevalence of Metabolic Syndrome in Alcohol Use Disorders: A Systematic Review and Meta-analysis. Alcohol and Alcoholism, Vol. 51, Issue. 5, p. 515.
Vancampfort, Davy Holt, Richard I.G. Stubbs, Brendon De Hert, Marc Samaras, Katherine and Mitchell, Alex J. 2016. Life-Threatening Effects of Antipsychotic Drugs.
Bartoli, Francesco Crocamo, Cristina Clerici, Massimo and Carrà, Giuseppe 2015. The association between PTSD and metabolic syndrome: A role for comorbid depression?. Metabolism, Vol. 64, Issue. 11, p. 1373.
Ha, Jee Hyun Park, Soyeon Yoon, Daehyun and Kim, Byungsu 2015. Short-term heart rate variability in older patients with newly diagnosed depression. Psychiatry Research, Vol. 226, Issue. 2-3, p. 484.
Individuals with depression have an elevated risk of cardiovascular disease (CVD) and metabolic syndrome (MetS) is an important risk factor for CVD. We aimed to clarify the prevalence and correlates of MetS in persons with robustly defined major depressive disorder (MDD).
We searched Medline, PsycINFO, EMBASE and CINAHL up until June 2013 for studies reporting MetS prevalences in individuals with MDD. Medical subject headings ‘metabolic’ OR ‘diabetes’ or ‘cardiovascular’ or ‘blood pressure’ or ‘glucose’ or ‘lipid’ AND ‘depression’ OR ‘depressive’ were used in the title, abstract or index term fields. Manual searches were conducted using reference lists from identified articles.
The initial electronic database search resulted in 91 valid hits. From candidate publications following exclusions, our search generated 18 studies with interview-defined depression (n = 5531, 38.9% male, mean age = 45.5 years). The overall proportion with MetS was 30.5% [95% confidence interval (CI) 26.3–35.1] using any standardized MetS criteria. Compared with age- and gender-matched control groups, individuals with MDD had a higher MetS prevalence [odds ratio (OR) 1.54, 95% CI 1.21–1.97, p = 0.001]. They also had a higher risk for hyperglycemia (OR 1.33, 95% CI 1.03–1.73, p = 0.03) and hypertriglyceridemia (OR 1.17, 95% CI 1.04–1.30, p = 0.008). Antipsychotic use (p < 0.05) significantly explained higher MetS prevalence estimates in MDD. Differences in MetS prevalences were not moderated by age, gender, geographical area, smoking, antidepressant use, presence of psychiatric co-morbidity, and median year of data collection.
The present findings strongly indicate that persons with MDD are a high-risk group for MetS and related cardiovascular morbidity and mortality. MetS risk may be highest in those prescribed antipsychotics.
This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
Email your librarian or administrator to recommend adding this journal to your organisation's collection.
Full text views reflects the number of PDF downloads, PDFs sent to Google Drive, Dropbox and Kindle and HTML full text views.
Abstract views reflect the number of visits to the article landing page.
* Views captured on Cambridge Core between September 2016 - 27th May 2017. This data will be updated every 24 hours.